COPD Co-infection With Tuberculosis on Th17 Cell Differentiation

Effect of COPD Co-infection With Tuberculosis on Th17 Cell Differentiation and Its Significance

This project will observe and follow up the changes of pulmonary function and CT in patients with smoking combined with pulmonary tuberculosis, and measure the ratio of Th1 cells, Th17 cells, macrophages and neutrophils and the secretion of factors such as TNF-α, IFN-γ and IL-17 in pulmonary blood and alveolar lavage fluid.

Study Overview

• Status: Completed
• Conditions: Chronic Obstructive Pulmonary Disease; Tuberculosis Infection
• Intervention / Treatment: Other: No intervention

Detailed Description

Chronic obstructive pulmonary disease (COPD) and tuberculosis are major global health problems, and acquired and acquired immunity play an important role in COPD and tuberculosis, and there is an interaction between COPD and tuberculosis, but the exact mechanism is not clear. Pre-existing TB infection is an independent risk factor for COPD and can aggravate pulmonary function and increase hospitalization and mortality in COPD patients. In COPD patients, Th1 and Th17 cells are involved in the development of COPD and emphysema through activation of macrophages and recruitment of neutrophils, while matrix metalloproteinases (MMPs) of macrophage and neutrophil origin are involved in the formation of tuberculosis cavities, and cytokines such as TNF-α, IFN-γ, IL-17 are involved in the mechanism of their destruction, IL-17 restricts the expression of HIF-1α to inhibit the development of TB granulomas, and CT analysis revealed that combined TB exacerbates emphysema in COPD patients. The above evidence suggests that tuberculosis plays an important role in the formation of emphysema in COPD. In this project, we will observe and follow up the changes of pulmonary function and CT in patients with smoking combined with pulmonary tuberculosis, and examine the ratio of Th1 cells, Th17 cells, macrophages and neutrophils and the secretion of TNF-α, IFN-γ, and IL-17 in pulmonary blood and alveolar lavage fluid.

• Study Type: Observational
• Enrollment (Actual): 80

Contacts and Locations

Study Locations

• China
  • Beijing
    • Beijing, Beijing, China, 100191
      • Peking University Third Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 40 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: N/A
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Patients seen at Peking University Third Hospital and Beijing Geriatric Hospital Respiratory Department from April 1, 2018 to April 1, 2020

Description

Inclusion Criteria:

• Clinical diagnosis of COPD
• age ≧ 40

Exclusion Criteria:

• Presence of other chronic respiratory diseases other than COPD, such as asthma, bronchiectasis, interstitial lung disease, etc.
• History of chest and lung surgery.
• History of malignancy.
• Autoimmune disease.
• Long-term oral glucocorticoids, immunosuppressants and inhaled glucocorticoids.
• Mental abnormalities, cognitive impairment, inability to cooperate with pulmonary function and other tests.
• Acute stage of infection, such as lung infection, urinary tract infection and gastrointestinal tract infection, etc.

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Prospective

Number of groups / cohorts

4

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
COPD combined with TB group; COPD combined with pulmonary TB infection	Other: No intervention; No intervention
COPD non-TB control group; COPD combined without pulmonary TB infection
TB non-COPD control group; pulmonary TB infection without COPD
Non-smoking non-TB control group; Non-smoking without pulmonary TB infection

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Differentiation of Th17 cells	Distribution of T cell subtypes, including CD4+, CD8+ T cells and Th17 cells, in blood specimens and alveolar lavage fluid by flow cytometry	Day 1

Collaborators and Investigators

• Sponsor: Peking University Third Hospital
• Collaborators: Beijing Geriatric Hospital
• Investigators: Principal Investigator: Yongchang Sun, MD, Peking University 3rd Hospital

Study record dates

Study Major Dates

• Study Start (Actual): April 1, 2018
• Primary Completion (Actual): April 1, 2020
• Study Completion (Actual): June 1, 2020

Study Registration Dates

• First Submitted: July 4, 2021
• First Submitted That Met QC Criteria: July 14, 2021
• First Posted (Actual): July 19, 2021

Study Record Updates

• Last Update Posted (Actual): July 19, 2021
• Last Update Submitted That Met QC Criteria: July 14, 2021
• Last Verified: July 1, 2020

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Respiratory Tract Diseases; Lung Diseases; Disease Attributes; Bacterial Infections; Bacterial Infections and Mycoses; Gram-Positive Bacterial Infections; Actinomycetales Infections; Mycobacterium Infections; Latent Infection; Lung Diseases, Obstructive; Pulmonary Disease, Chronic Obstructive; Infections; Communicable Diseases; Tuberculosis; Latent Tuberculosis; Coinfection
• Other Study ID Numbers: M2017390

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No